Varicella Zoster (HHV-3) Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Varicella Zoster (HHV-3) Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), causes two distinct infections: chickenpox (varicella) and shingles (herpes zoster). Varicella is a highly contagious viral infection characterized by an itchy rash with red spots and fluid-filled blisters that break open and form scabs. It spreads through respiratory droplets and direct contact with the rash. Varicella commonly affects children, and symptoms besides the rash include fever, fatigue, and loss of appetite. The illness usually resolves within 1-2 weeks. However, after the primary infection of chickenpox, VZV can remain dormant in nerve cells. Later in life or when the immune system weakens, the virus may reactivate, causing shingles. Shingles manifests as a painful rash that typically appears on one side of the body, often in a band-like pattern along a nerve pathway. Other symptoms may include burning, tingling, or shooting pain. It usually lasts for several weeks.
The Varicella Zoster (HHV-3) Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Varicella Zoster (HHV-3) Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 68 molecules, with 65 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Varicella Zoster (HHV-3) Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Varicella Zoster (HHV-3) Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Varicella Zoster (HHV-3) Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adjuvance Technologies IncAmytrx Therapeutics Inc
Barinthus Biotherapeutics Plc
Beijing Green Bamboo Biotechnology Co Ltd
Beijing Health Guard Biotechnology Inc
Beijing Institute of Biological Products
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Minhai Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
Biological E Ltd
BioNTech SE
BMI Korea Co Ltd
BravoVax Co Ltd
CanSino Biologics Inc
CHA Vaccine Institute Co Ltd
Changchun Institute of Biological Products Co Ltd
China National Pharmaceutical Group Corp
Chongqing Zhifei Biological Products Co Ltd
Curevo Inc
DongKoo Bio & Pharma Co Ltd
Dynavax Technologies Corp
EyeGene Inc
Fort Lewis College
Genrix (Shanghai) Biopharmaceutical Co Ltd
GreenLight Biosciences Holdings PBC
GSK plc
HDT Bio Corp
Immorna Hangzhou Biotechnology Co Ltd
Indian Immunologicals Ltd
Jiangsu Recbio Technology Co Ltd
Lee's Pharmaceutical Holdings Ltd
Liaoning Chengda Biological Co Ltd
MAXVAX Biotechnology Co Ltd
Mayly Life Sciences
Moderna Inc
NAL Pharmaceuticals Ltd
Nanjing Yuandasai Weixin Biomedical Co Ltd
NanoViricides Inc
Pfizer Inc
RNAimmune Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Institute of Biological Products Co Ltd
Shanghai Yidao Biological Technology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
Shulov Innovative Science Ltd
SK Bioscience Ltd
Stemirna Therapeutics Ltd
Suzhou Abogen Biosciences Co Ltd
TTY Biopharm Co Ltd
Vapogenix Inc
Varnotech
Vernagen Inc
ViroStatics SRL
Walvax Biotechnology Co Ltd
Wintermute Biomedical LLC
XBiotech Inc
Yisheng Biopharma Co Ltd
Zhongyianke Biotech Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Varicella Zoster (HHV-3) Infections reports